The Predictive and Presymptomatic Testing Market size was valued at USD 5.08 Billion in 2023 and the total Predictive and Presymptomatic Testing revenue is expected to grow at a CAGR of 9.6% from 2024 to 2030, reaching nearly USD 9.66 Billion. The global Predictive and Presymptomatic Testing Market report is a comprehensive analysis of the industry, market, and key players. The report has covered the market by demand and supply-side by segments. The global Predictive and Presymptomatic Testing Market report also provides trends by market segments, technology, and investment with a competitive landscape.Global Predictive and Presymptomatic Testing Market Overview:
Presymptomatic testing (PST) is a genetic test carried out on an individual that has no irregular symptoms or an asymptomatic individual to determine whether the person has a hereditary disease-causing mutation or any genetic disorders that can lead to genetic disorders in the future. Further, this test is carried out to identify whether a person will develop a genetic disorder in the future or not and reduce the rising occurrence of genetic disorders. Predictive genetic testing is the use of a genetic test in an asymptomatic person to predict future risk of disease. These tests represent a new and growing class of medical tests, differing in fundamental ways from conventional medical diagnostic tests.To know about the Research Methodology :- Request Free Sample Report
Global Predictive and Presymptomatic Testing Market Dynamics:
The predictive and presymptomatic testing market expected to grow at CAGR of 9.6% during the forecast year of 2024-2030 due to growing genetic disorders and genetic counseling. Resources and technological advancement have played a great role in genetic counseling. As per medical conditions, 10% of individuals are suffering from genetic defects, however, it's a minor disease. Some of the common genetic disorders are Down syndrome, Thalassemia, Cystic fibrosis, sickle cell anemia, and various others. As per Proceeding National Academy of Science of North America, around 2.7 billion people (36% of the total world population) worldwide are the carrier of at least one mutation that causes AR-IRD that is autosomal recessive (AR) inherited retinal diseases (IRDs). Moreover, modern technologies and the latest innovations concerning genetic disorders are boosting the market growth of the predictive and presymptomatic testing market. Also, there is no cure for genetic disorders; they can only be treated and not cured fully.Global Predictive and Presymptomatic Testing Market Segment Analysis:
By Condition, the segment is divided into Breast and Ovarian Cancer, Colorectal Cancer, Alzheimer’s disease, Multiple Endocrine Neoplasia Type – 2, Haemochromatosis. Breast and Ovarian Cancer is dominating the conditioning segment of the Predictive and Presymptomatic Testing market and is estimated to witness the highest CAGR in the forecast period of 2024-2030. Cancers included in the conditioning segment are not genetic disorders but are greatly controlled by genes in the body and are passed from one generation to another. The identification of BRCA1 and BRCA that Breast Cancer Gene in 1994-1995 leads to the testing of presymptomatic DNA testing for autosomal dominant hereditary breast and ovarian cancer. Every healthy mutation carrier of the BRCA gene has a high risk of breast cancer and ovarian cancer for a lifetime. Moreover, India and America are the countries where women are highly suffered from breast cancer every year. In India, the total number of breast cancer frequency cases was valued at 7,12,758 in 2020 and estimated to reach 8,06,218 by 2025 in women. The number of breast cancer cases that is 2,38,908 is expected to be the most common cancer forecast period, followed by cancer in the lung (1,11,328) and mouth (90,060) in the future. Additionally, around 2.3 million breast cancer cases were reported in women and 685000 deaths were caused due to breast cancer globally in the year 2020. Further, the rate has decreased due to high technological investments and precise medications with advanced therapy like oral chemotherapy and a target drug delivery system.Global Predictive and Presymptomatic Testing Market Regional Insights:
North America is dominating the predictive and presymptomatic testing market regional insight. The major countries of North America are the US, Mexico, and Canada. Among these, the US was valued at USD 1.12 billion in the year 2020. In 2020, an estimated 276,480 new cases of proliferating breast cancer were diagnosed in women in the U.S. 65% of breast cancer cases are diagnosed at a localized stage, in which 5-year survival is 98%. Additionally, North America is ranked highest in breast cancer treatment due to the occurrence of breast cancer cases in women. Further, the high technological investment in the region with growing healthcare facilities with advanced infrastructure are fuelling the market growth of predictive and presymptomatic testing in the regional market. The objective of the report is to present a comprehensive analysis of the global Market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding the global Market dynamics, structure by analyzing the market segments and project the global Market size. Clear representation of competitive analysis of key players by Grade, price, financial position, Grade portfolio, growth strategies, and regional presence in the global Market make the report investor’s guide.Global Predictive and Presymptomatic Testing Market Scope: Inquire before buying
Global Predictive and Presymptomatic Testing Market Report Coverage Details Base Year: 2023 Forecast Period: 2024-2030 Historical Data: 2018 to 2023 Market Size in 2023: USD 5.08 Bn. Forecast Period 2024 to 2030 CAGR: 9.6% Market Size in 2030: USD 9.66 Bn. Segments Covered: by Condition Breast and Ovarian Cancer Colorectal Cancer Alzheimer's Disease Multiple Endocrine Neoplasia Type 2 Haemochromatosis Global Predictive and Presymptomatic Testing Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Global Predictive and Presymptomatic Testing Market Key Player
1. 23andMe, Inc. 2. Abbott Molecular, Inc. 3. BioAxis DNA Research Centre Private Limited 4. Color Genomics, Inc. 5. Direct Laboratory Services LLC (DirectLabs) 6. Gene by Gene Ltd. 7. Genomic Diagnostics 8. Mapmygenome 9. Myriad Genetics, Inc. 10. Pathway Genomics Corporation 11. Positive Bioscience, Inc. 12. Quest Diagnostics, Inc Frequently Asked Questions: 1. Which region has the largest share in Global Predictive and Presymptomatic Testing Market? Ans: North America region held the highest share in 2023. 2. What was the Global Predictive and Presymptomatic Testing Market size in 2023? Ans: The Global Predictive and Presymptomatic Testing Market size was USD 5.08 Billion in 2023. 3. What is scope of the Global Predictive and Presymptomatic Testing Market report? Ans: Global Predictive and Presymptomatic Testing Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period. 4. Who are the key players in Global Predictive and Presymptomatic Testing Market? Ans: The important key players in the Global Xyz Market are – 23andMe, Inc., Abbott Molecular, Inc., BioAxis DNA Research Centre Private Limited, Color Genomics, Inc., Direct Laboratory Services LLC (DirectLabs), Gene by Gene Ltd., Genomic Diagnostics, Mapmygenome, Myriad Genetics, Inc., Pathway Genomics Corporation, Positive Bioscience, Inc., Quest Diagnostics, Inc. 5. What is the study period of this Market? Ans: The Global Predictive and Presymptomatic Testing Market is studied from 2023 to 2030.
1. Preface 1.1. Market Definition and Key Research Objectives 1.2. Research Highlights 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Predictive and Presymptomatic Testing Market Size, by Market Value (US$ Mn) 3.1. Global Market Segmentation 3.2. Global Market Segmentation Share Analysis, 2019 3.2.1. Global 3.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 3.3. Geographical Snapshot of the Predictive and Presymptomatic Testing Market 3.4. Geographical Snapshot of the Predictive and Presymptomatic Testing Market, By Manufacturer share 4. Global Predictive and Presymptomatic Testing Market Overview, 2023-2030 4.1. Market Dynamics 4.1.1. Drivers 4.1.1.1. Global 4.1.1.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.2. Restraints 4.1.2.1. Global 4.1.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.3. Opportunities 4.1.3.1. Global 4.1.3.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.4. Challenges 4.1.4.1. Global 4.1.4.2. By Region (North America, Europe, Asia Pacific, South America, Middle East Africa) 4.1.5. Industry Trends and Emerging Technologies 4.1.6. Porters Five Forces Analysis 4.1.6.1. Threat of New Entrants 4.1.6.2. Bargaining Power of Buyers/Consumers 4.1.6.3. Bargaining Power of Suppliers 4.1.6.4. Threat of Substitute Grades 4.1.6.5. Intensity of Competitive Rivalry 4.1.7. Value Chain Analysis 4.1.8. Technological Roadmap 4.1.9. Regulatory landscape 4.1.10. Impact of the Covid-19 Pandemic on the Global Predictive and Presymptomatic Testing Market 5. Supply Side and Demand Side Indicators 6. Global Predictive and Presymptomatic Testing Market Analysis and Forecast, 2023-2030 6.1. Global Predictive and Presymptomatic Testing Market Size & Y-o-Y Growth Analysis. 7. Global Predictive and Presymptomatic Testing Market Analysis and Forecasts, 2023-2030 7.1. Other Market Size (Value) Estimates & Forecast By Condition, 2023-2030 7.1.1. Breast and Ovarian Cancer 7.1.2. Colorectal Cancer 7.1.3. Alzheimer's Disease 7.1.4. Multiple Endocrine Neoplasia Type 2 7.1.5. Haemochromatosis 8. Global Predictive and Presymptomatic Testing Market Analysis and Forecasts, By Region 8.1. Market Size (Value) Estimates & Forecast By Region, 2023-2030 8.1.1. North America 8.1.2. Europe 8.1.3. Asia-Pacific 8.1.4. Middle East & Africa 8.1.5. South America 9. North America Predictive and Presymptomatic Testing Market Analysis and Forecasts, 2023-2030 9.1. Market Size (Value) Estimates & Forecast By Condition, 2023-2030 9.1.1. Breast and Ovarian Cancer 9.1.2. Colorectal Cancer 9.1.3. Alzheimer's Disease 9.1.4. Multiple Endocrine Neoplasia Type 2 9.1.5. Haemochromatosis 10. North America Predictive and Presymptomatic Testing Market Analysis and Forecasts, By Country 10.1. Market Size (Value) Estimates & Forecast By Country, 2023-2030 10.1.1. US 10.1.2. Canada 10.1.3. Mexico 11. U.S. Predictive and Presymptomatic Testing Market Analysis and Forecasts, 2023-2030 11.1. Market Size (Value) Estimates & Forecast By Condition, 2023-2030 12. Canada Predictive and Presymptomatic Testing Market Analysis and Forecasts, 2023-2030 12.1. Market Size (Value) Estimates & Forecast By Condition, 2023-2030 13. Mexico Predictive and Presymptomatic Testing Market Analysis and Forecasts, 2023-2030 13.1. Market Size (Value) Estimates & Forecast By Condition, 2023-2030 14. Europe Predictive and Presymptomatic Testing Market Analysis and Forecasts, 2023-2030 14.1. Market Size (Value) Estimates & Forecast By Condition, 2023-2030 15. Europe Predictive and Presymptomatic Testing Market Analysis and Forecasts, By Country 15.1. Market Size (Value) Estimates & Forecast By Country, 2023-2030 15.1.1. U.K 15.1.2. France 15.1.3. Germany 15.1.4. Italy 15.1.5. Spain 15.1.6. Sweden 15.1.7. CIS Countries 15.1.8. Rest of Europe 16. U.K Predictive and Presymptomatic Testing Market Analysis and Forecasts, 2023-2030 16.1. Market Size (Value) Estimates & Forecast By Condition, 2023-2030 17. France Predictive and Presymptomatic Testing Market Analysis and Forecasts, 2023-2030 17.1. Market Size (Value) Estimates & Forecast By Condition, 2023-2030 18. Germany Predictive and Presymptomatic Testing Market Analysis and Forecasts, 2023-2030 18.1. Market Size (Value) Estimates & Forecast By Condition, 2023-2030 19. Italy Predictive and Presymptomatic Testing Market Analysis and Forecasts, 2023-2030 19.1. Market Size (Value) Estimates & Forecast By Condition, 2023-2030 20. Spain Predictive and Presymptomatic Testing Market Analysis and Forecasts, 2023-2030 20.1. Market Size (Value) Estimates & Forecast By Condition, 2023-2030 21. Sweden Predictive and Presymptomatic Testing Market Analysis and Forecasts, 2023-2030 Market Size (Value) Estimates & Forecast By Condition, 2023-2030 22. CIS Countries Predictive and Presymptomatic Testing Market Analysis and Forecasts, 2023-2030 22.1. Market Size (Value) Estimates & Forecast By Condition, 2023-2030 23. Rest of Europe Predictive and Presymptomatic Testing Market Analysis and Forecasts, 2023-2030 23.1. Market Size (Value) Estimates & Forecast By Condition, 2023-2030 24. Asia Pacific Predictive and Presymptomatic Testing Market Analysis and Forecasts, 2023-2030 24.1. Market Size (Value) Estimates & Forecast By Condition, 2023-2030 25. Asia Pacific Predictive and Presymptomatic Testing Market Analysis and Forecasts, by Country 25.1. Market Size (Value) Estimates & Forecast By Country, 2023-2030 25.1.1. China 25.1.2. India 25.1.3. Japan 25.1.4. South Korea 25.1.5. Australia 25.1.6. ASEAN 25.1.7. Rest of Asia Pacific 26. China Predictive and Presymptomatic Testing Market Analysis and Forecasts, 2023-2030 26.1. Market Size (Value) Estimates & Forecast By Condition, 2023-2030 27. India Predictive and Presymptomatic Testing Market Analysis and Forecasts, 2023-2030 27.1. Market Size (Value) Estimates & Forecast By Condition, 2023-2030 28. Japan Predictive and Presymptomatic Testing Market Analysis and Forecasts, 2023-2030 28.1. Market Size (Value) Estimates & Forecast By Condition, 2023-2030 29. South Korea Predictive and Presymptomatic Testing Market Analysis and Forecasts, 2023-2030 29.1. Market Size (Value) Estimates & Forecast By Condition, 2023-2030 30. Australia Predictive and Presymptomatic Testing Market Analysis and Forecasts, 2023-2030 30.1. Market Size (Value) Estimates & Forecast By Condition, 2023-2030 31. ASEAN Predictive and Presymptomatic Testing Market Analysis and Forecasts, 2023-2030 31.1. Market Size (Value) Estimates & Forecast By Condition, 2023-2030 32. Rest of Asia Pacific Predictive and Presymptomatic Testing Market Analysis and Forecasts, 2023-2030 32.1. Market Size (Value) Estimates & Forecast By Condition, 2023-2030 33. Middle East Africa Predictive and Presymptomatic Testing Market Analysis and Forecasts, 2023-2030 33.1. Market Size (Value) Estimates & Forecast By Condition, 2023-2030 34. Middle East Africa Predictive and Presymptomatic Testing Market Analysis and Forecasts, by Country 34.1. Market Size (Value) Estimates & Forecast by Country, 2023-2030 34.1.1. South Africa 34.1.2. GCC Countries 34.1.3. Egypt 34.1.4. Nigeria 34.1.5. Rest of ME&A 35. South Africa Predictive and Presymptomatic Testing Market Analysis and Forecasts, 2023-2030 35.1. Market Size (Value) Estimates & Forecast By Condition, 2023-2030 36. GCC Countries Predictive and Presymptomatic Testing Market Analysis and Forecasts, 2023-2030 36.1. Market Size (Value) Estimates & Forecast By Condition, 2023-2030 37. Egypt Textile Reinforced Concrete e Market Analysis and Forecasts, 2023-2030 37.1. Market Size (Value) Estimates & Forecast By Condition, 2023-2030 38. Nigeria Predictive and Presymptomatic Testing Market Analysis and Forecasts, 2023-2030 38.1. Market Size (Value) Estimates & Forecast By Condition, 2023-2030 39. Rest of ME&A Predictive and Presymptomatic Testing Market Analysis and Forecasts, 2023-2030 39.1. Market Size (Value) Estimates & Forecast By Condition, 2023-2030 40. South America Predictive and Presymptomatic Testing Market Analysis and Forecasts, 2023-2030 40.1. Market Size (Value) Estimates & Forecast By Condition, 2023-2030 41. South America Predictive and Presymptomatic Testing Market Analysis and Forecasts, by Country 41.1. Market Size (Value) Estimates & Forecast by Country, 2023-2030 41.1.1. Brazil 41.1.2. Argentina 41.1.3. Rest of South America 42. Brazil Predictive and Presymptomatic Testing Market Analysis and Forecasts, 2023-2030 42.1. Market Size (Value) Estimates & Forecast By Condition, 2023-2030 43. Argentina Predictive and Presymptomatic Testing Market Analysis and Forecasts, 2023-2030 43.1. Market Size (Value) Estimates & Forecast By Types, 2023-2030 43.2. Market Size (Value) Estimates & Forecast By Condition, 2023-2030 44. Rest of South America Predictive and Presymptomatic Testing Market Analysis and Forecasts, 2023-2030 44.1. Market Size (Value) Estimates & Forecast By Condition, 2023-2030 45. Competitive Landscape 45.1. Geographic Footprint of Major Players in the Global Predictive and Presymptomatic Testing Market 45.2. Competition Matrix 45.2.1. Competitive Benchmarking of Key Players By Price, Presence, Market Share, Fiber Grades and R&D Investment 45.2.2. New Grade Launches and Grade Enhancements 45.2.3. Market Consolidation 45.2.3.1. M&A by Regions, Investment and Verticals 45.2.3.2. M&A, Forward Integration and Backward Integration 45.2.3.3. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements 45.3. Company Profile : Key Players 45.3.1. PerkinElmer 45.3.1.1. Company Overview 45.3.1.2. Financial Overview 45.3.1.3. Geographic Footprint 45.3.1.4. Grade Portfolio 45.3.1.5. Business Strategy 45.3.1.6. Recent Developments 45.3.2. 23andMe, Inc. 45.3.3. Abbott Molecular, Inc. 45.3.4. BioAxis DNA Research Centre Private Limited 45.3.5. Color Genomics, Inc. 45.3.6. Direct Laboratory Services LLC (DirectLabs) 45.3.7. Gene by Gene Ltd. 45.3.8. Genomic Diagnostics 45.3.9. Mapmygenome 45.3.10. Myriad Genetics, Inc. 45.3.11. Pathway Genomics Corporation 45.3.12. Positive Bioscience, Inc. 45.3.13. Quest Diagnostics, Inc 46. Primary Key Insights
